Hosted on MSN4h
Wells Fargo Downgrades Exelixis (EXEL)
Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...
Exelixis downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...
Wells Fargo downgrades Exelixis, says take profits after rally
Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
Co-Diagnostics, Inc. (NASDAQ:CODX) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in ...
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | Delveinsight
The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...
Hosted on MSN4h
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value ...
Photodynamic Therapies In Oncology Market Is Predicted To Exhibit Remarkable Growth During The Study Period (2020–2034) | Delveinsight
The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...